Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Blackrock Inc (BLK) vs ResMed Inc. (RMD) Price & Performance

Blackrock IncTrade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

Blackrock Inc vs ResMed Inc. — how do they compare? Blackrock Inc trades at $1,144.15 (market cap $175.22B), while ResMed Inc. trades at $223.62 (market cap $31.92B). The key difference: Blackrock Inc is far larger — about 5.5× ResMed Inc.'s market cap, and Blackrock Inc pays the higher dividend (2.03%). Which is the better fit depends on your goals.

BLKRMD
Market Cap
$175.22B$31.92B
Volume
641,547
Sector
FinancialsHealth
52-Week High
$1.20K$293.73
52-Week Low
$922.90$182.82
Enterprise Value
$176.32B$31.28B
Dividend Yield
2.03%1.2%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Blackrock Inc

No Aura AI signal available yet.

ResMed Inc.

ResMed (RMD) trades at $211.94, down 5.06% on the day, following a Q4 2026 earnings beat but weaker fiscal 2027 revenue guidance. The stock shows strong fundamentals with a 26.94% net income margin and consistent earnings beats, while technical indicators are neutral with support at $204 and resistance at $218. Recent news highlights growth in sleep device demand but concerns over sales forecasts.

Outlook remains mixed: robust profitability and a $235 consensus price target suggest upside, but near-term pressure from guidance and technical neutrality poses risks. Investors should weigh solid financial health against market sentiment shifts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Blackrock Inc

BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.

Read more on BLK

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD